Globalization

Clinical Trial Globalization Trends

Scroll down for details.

Sources


CTM provides three sources of information in relation to the globalization of industry sponsored clinical trials:
• ❶ A recent comprehensive Report.
• ❷ A weekly newsletter: CTM Weekly.
• ❸ Ongoing country Ranking.

Why follow the globalization trend?


Many countries are interested in attracting more industry-sponsored clinical trials since they come with financial revenue and educational activities. For this reason, it is important to follow the development on a global level, not just locally.

Regulatory changes and infrastructure development have a clear impact on the number of trials that are conducted in a certain country. An example is South Korea, which has become a leading clinical trial country not only in Asia but also globally.

Some countries are becoming less attractive since the start-up time of a clinical trial is much longer than other countries. One example is Brazil.

Regulatory changes can act as a break. An example is India that during the past few years fell from the 11th position place globally to 30th place. The downwards trend is still ongoing.

Monitoring the globalization of industry-sponsored clinical trials is thus important not only for the industry, but also regulatory authorities, government bodies, the academia and the individual investigator.

Download


Globalization of Industry-Sponsored Clinical Trials

CTM Report - Globalization of Industry-Sponsored Clinical Trials - Cover PageAuthor: Johan PE Karlberg

Published by: Clinical Trial Magnifier Limited

Published: 2014

Summary: This report represents an in-depth analysis of all Phase II/III industry-sponsored clinical trials registered in the US Trials Registry, initiated between July 2006 to June 2013. The number of such trials has been fairly constant over the seven years of observation, with an annual average of 2,000 trials initiated, providing 60,000 new study sites and close to 800,000 participants annually. North America and the European continent make up 81.4 percent of all sites, leaving only a relatively small portion for the rest of the world to compete for. We may also conclude that the globalization of industry-sponsored clinical trials has partially or fully halted.

Note: From February 2015, distributed by Clinical Trial Magnifier Limited only.

Clinical-Trial-Magnifier-Download

Download Report (5464 downloads)

CTM Weekly newsletter


Clinical Trial Magnifier Weekly brings you new information about essential weekly changes in the 60,000 industry-sponsored clinical studies of the US trial registry – clinicaltrials.gov.

Clinical Trial Magnifier Weekly sorts through tens of thousands of records and extracts the pivotal information you need. You’ll be able to scan through all the changes and drill down using links in the Excel file, saving you hours of effort.

Clinical Trial Magnifier Weekly breaks information down into many detailed tables in sortable spread sheet format, perfect for analysis.

You will be able to identify new clinical trial opportunities in your area of interest and in the region that you are active in.

Read more Newsletter

Country Ranking


The US trials registry (www.clinicaltrials.gov) includes over 150.000 clinical trials, of which one third are industry-sponsored clinical studies. The US trials registry is the most comprehensive registry. It has been estimated that 60%-70% of all industry-sponsored clinical trials are listed in the registry. We can thus use the US trials registry with confidence to visualize the globalization of industry-sponsored clinical trials.

The two tables below include the number of trial sites by continent and country.

Globalization of clinical trials - searchable tables


The tables below include the number of trial sites by continent and country.

The table files include information for all interventional treatment phase II/III trials registered during the past four years.

Updated on May 18 2017.

Please note that the percentage represents the number of sites of the global count.

Table 1. Ranking between continents: Total number of sites for phase II/III treatment trials registered in the US trials registry (past four years).
CONTINENT RANK SITES (N) SITES (%)
1. N AMERICA 1 100489 41.28
2. L AMERICA 5 009927 04.08
3. EUROPE 2 056167 23.07
4. EAST EUROPE 3 034792 14.29
5. MIDDLE EAST 7 002733 01.12
6. AFRICA 8 001748 00.72
7. ASIA 4 032482 13.34
8. OCEANIA 6 005084 02.09

Table 2. Ranking between countries: Total number of sites for phase II/III treatment trials registered in the US trials registry (past four years).
COUNTRY RANK SITES (N) SITES (%)
ALGERIA 066 000034 00.01
AMERICAN SAMOA 093 000006 00.00
ARGENTINA 020 002496 01.03
AUSTRALIA 013 004412 01.81
AUSTRIA 029 001280 00.53
BAHRAIN 109 000002 00.00
BANGLADESH 088 000007 00.00
BELARUS 055 000181 00.07
BELGIUM 017 003239 01.33
BELIZE 080 000009 00.00
BENIN 119 000001 00.00
BOLIVIA 106 000002 00.00
BOSNIA AND HERZEGOVINA 057 000098 00.04
BOTSWANA 096 000004 00.00
BRAZIL 018 003128 01.29
BULGARIA 022 002403 00.99
BURKINA FASO 084 000008 00.00
CAMEROON 110 000002 00.00
CANADA 007 006937 02.85
CHILE 037 000780 00.32
CHINA 011 005958 02.45
COLOMBIA 041 000658 00.27
COSTA RICA 072 000020 00.01
COTE DIVOIRE 097 000004 00.00
CROATIA 047 000422 00.17
CUBA 094 000004 00.00
CYPRUS 095 000004 00.00
CZECH REPUBLIC 016 003331 01.37
DENMARK 034 001054 00.43
DOMINICAN REPUBLIC 065 000037 00.02
ECUADOR 074 000017 00.01
EGYPT 056 000104 00.04
EL SALVADOR 081 000009 00.00
ESTONIA 045 000441 00.18
ETHIOPIA 111 000002 00.00
FINLAND 035 000848 00.35
FRANCE 005 008012 03.29
GABON 101 000003 00.00
GAMBIA 112 000002 00.00
GEORGIA 052 000347 00.14
GERMANY 003 011217 04.61
GHANA 102 000003 00.00
GREECE 033 001129 00.46
GUATEMALA 060 000070 00.03
HONDURAS 079 000010 00.00
HONG KONG 053 000336 00.14
HUNGARY 014 003844 01.58
ICELAND 076 000014 00.01
INDIA 027 001548 00.64
INDONESIA 064 000038 00.02
IRAN 078 000011 00.00
IRELAND 050 000390 00.16
ISRAEL 021 002491 01.02
ITALY 008 006899 02.83
JAMAICA 082 000008 00.00
JAPAN 002 014626 06.01
JORDAN 073 000019 00.01
KAZAKHSTAN 075 000016 00.01
KENYA 068 000026 00.01
KOREA, SOUTH 012 004953 02.03
KUWAIT 089 000006 00.00
LATVIA 044 000500 00.21
LEBANON 058 000098 00.04
LITHUANIA 046 000428 00.18
LUXEMBOURG 086 000007 00.00
MACEDONIA 070 000024 00.01
MALAWI 120 000001 00.00
MALAYSIA 043 000516 00.21
MALI 098 000004 00.00
MAURITIUS 087 000007 00.00
MEXICO 024 002057 00.85
MOLDOVA, REPUBLIC OF 062 000054 00.02
MONACO 108 000002 00.00
MONGOLIA 100 000004 00.00
MOROCCO 071 000023 00.01
MOZAMBIQUE 099 000004 00.00
NEPAL 122 000001 00.00
NETHERLANDS 023 002109 00.87
NEW ZEALAND 040 000666 00.27
NICARAGUA 116 000001 00.00
NIGER 121 000001 00.00
NIGERIA 103 000003 00.00
NORWAY 049 000397 00.16
OMAN 090 000006 00.00
PAKISTAN 123 000001 00.00
PANAMA 063 000047 00.02
PARAGUAY 107 000002 00.00
PERU 042 000570 00.23
PHILIPPINES 048 000418 00.17
POLAND 009 006823 02.80
PORTUGAL 032 001164 00.48
QATAR 083 000008 00.00
ROMANIA 025 002001 00.82
RUSSIA 010 006758 02.78
RWANDA 113 000002 00.00
SAUDI ARABIA 061 000067 00.03
SENEGAL 114 000002 00.00
SERBIA 036 000835 00.34
SIERRA LEONE 091 000006 00.00
SINGAPORE 051 000349 00.14
SLOVAKIA 030 001258 00.52
SLOVENIA 059 000081 00.03
SOUTH AFRICA 028 001445 00.59
SPAIN 004 009347 03.84
SRI LANKA 085 000008 00.00
SWAZILAND 115 000002 00.00
SWEDEN 031 001215 00.50
SWITZERLAND 038 000751 00.31
TAIWAN 019 002499 01.03
TANZANIA 092 000006 00.00
THAILAND 039 000666 00.27
TUNISIA 067 000030 00.01
TURKEY 026 001957 00.80
UGANDA 077 000013 00.01
UKRAINE 015 003353 01.38
UNITED ARAB EMIRATES 069 000025 00.01
UNITED KINGDOM 006 007089 02.91
UNITED STATES 001 093552 38.43
URUGUAY 117 000001 00.00
VENEZUELA 118 000001 00.00
VIETNAM 054 000191 00.08
ZAMBIA 104 000003 00.00
ZIMBABWE 105 000003 00.00

Clinical-Trial-Magnifier-Globalization-Unclear

“No one can predict the future exactly, but we know two things:
it's going to be different, and it must be rooted in today's world.”
Peter Thiel

If you have additional advices, questions, or comments on the contents of this page, please send us a message: Contact